Bioequivalence
Bioequivalence — The demonstration that two formulations of the same compound produce equivalent biological effects, a key consideration in generic peptide development.
What Is Bioequivalence?
Bioequivalence demonstrates that two peptide formulations produce the same systemic exposure (AUC and Cmax within 80-125% of reference). Bioequivalence studies are required for generic peptide drug approval, showing that a follow-on product performs identically to the reference product without requiring full clinical efficacy trials.
Study Design
- Crossover: Each subject receives both test and reference formulations with washout period
- PK endpoints: AUC0-inf, AUC0-t, and Cmax compared. 90% confidence interval must fall within 80-125%
- Peptide challenges: High immunogenicity and variable absorption complicate peptide bioequivalence studies
Frequently Asked Questions
What is Bioequivalence?
The demonstration that two formulations of the same compound produce equivalent biological effects, a key consideration in generic peptide development.
Why is Bioequivalence important in peptide research?
Bioequivalence is a fundamental concept in pharmacology as it relates to peptide science. It directly influences experimental design, compound characterization, and the reliability of research outcomes across biochemistry and molecular biology disciplines.
Authority Sources
- Bioequivalence on Wikipedia
- Search Bioequivalence on PubChem (NIH)
- Research articles on ScienceDirect